首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1732135

全球吸藥輔助器市場規模（按類型、分銷管道、區域範圍和預測）

Global Asthma Spacers Market Size By Type (Volumatic, Aerochamber, Inspirease, Optichamber), By Distribution Channel (Hospitals, Retail, Online), By Geographic Scope And Forecast

出版日期: 2025年04月29日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

吸藥輔助器市場規模及預測

2024 年吸藥輔助器市場規模價值 20.9 億美元，預計到 2032 年將達到 26.3 億美元，2026 年至 2032 年的複合年成長率為 3.21%。

儲霧罐是一種用於提高氣喘治療定量吸入器 (MDI) 藥效的裝置。儲霧罐通常由一根管子組成，一端連接到吸入器，另一端連接吸嘴或面罩。當藥物從吸入器釋放時，它會進入儲霧罐，使使用者能夠更緩慢、更深地吸入，從而改善藥物向肺部的輸送，並降低口腔潰瘍等副作用的可能性。

對於那些難以協調使用吸入器的人來說，例如幼兒或有嚴重呼吸問題的人，儲霧罐也特別有用，它們還可以幫助更多的藥物到達呼吸道，而不會沉積在口腔和喉嚨中。

吸藥輔助器的全球市場動態

影響吸藥輔助器市場的關鍵市場動態是：

關鍵市場促進因素

全球氣喘盛行率不斷上升：全球氣喘患者數量的不斷成長是吸藥輔助器市場的主要驅動力。根據世界衛生組織 (WHO) 的數據，2019 年氣喘影響了約 2.62 億人，奪走了 46.1 萬人的生命。根據全球氣喘網路 (Global Asthma Network) 發布的《2022 年全球氣喘報告》，過去十年氣喘盛行率上升了 3.6%。患者群體的不斷擴大催生了對更有效的氣喘控制技術（例如間隔器）的需求。

空氣污染程度上升與環境誘因：空氣污染加劇和環境變數加劇會加重氣喘症狀，因此需要使用儲霧槽等有效的藥物傳遞方式。根據世界銀行的數據，每10人就有9人呼吸著污染的空氣。根據2022年發表在《刺胳針星球健康》上的一項研究，空氣污染每年導致兒童氣喘病例增加180萬例。空氣品質與氣喘發病之間的關聯凸顯了對儲霧槽等氣喘管理設備日益成長的需求。

提高對正確吸入技術的認知和教育：病患教育和對正確吸入技術的日益重視，正在推動使用儲霧罐來改善藥物輸送並預防副作用。 2019年發表在《氣喘雜誌》上的一項系統性回顧發現，只有31%的患者使用了正確的吸入技術。使用儲霧罐可以顯著改善藥物分佈。英國國家健康與照護卓越研究所 (NICE)建議所有使用壓力定量吸入器 (pMDI) 的12歲以下兒童都應使用儲霧槽。據英國哮喘協會稱，正確使用儲霧罐可以將藥物輸送到肺部的量提高10%至50%。

主要挑戰

高成本：氣喘儲霧罐的高昂價格是市場面臨的一大挑戰。許多氣喘患者，尤其是低收入患者，難以負擔儲霧罐的價格，從而限制了儲霧罐的供應和可及性。這一成本障礙不僅影響個別患者，也限制了整個市場的成長，因為醫療保健提供者不願意提案患者無法負擔的產品。因此，有效的氣喘控制技術往往未被充分利用。

來自替代設備的競爭：吸藥輔助器市場面臨來自霧化器和乾粉吸入器 (DPI) 等替代設備的額外競爭。一些消費者和醫療保健提供者更青睞這些替代品。因此，吸藥輔助器製造商必須努力突顯其各自的優勢，並確保滿足患者和醫療保健系統不斷變化的需求，從而實現產品差異化。這種競爭環境使間隔器製造商的市場定位和成長策略變得更加複雜。

主要趨勢：

更重視預防性醫療保健：隨著醫療保健系統更加重視在氣喘等慢性疾病惡化之前進行治療，氣喘儲霧罐已成為綜合治療方法的重要組成部分。這些裝置可以改善藥物輸送，並減少氣喘發作的次數和嚴重程度。這種向預防性干預的轉變不僅改善了患者的預後，也滿足了更大的醫療保健成本削減目標，從而增加了對儲霧罐的需求。

新興市場應用日益普及：隨著氣喘治療意識的增強以及吸入療法益處的不斷增加，氣喘高發地區對有效給藥裝置的需求日益成長。隨著醫療基礎設施的改善以及氣喘控制產品可近性的提高，製造商正努力提高這些地區的滲透率。這些發展為吸藥輔助器市場創造了巨大的成長機會。

A spacer is a device that improves the efficiency of metered-dose inhalers (MDIs) used to deliver asthma treatments. It usually comprises a tube connected to the inhaler on one end and a mouthpiece or mask on the other. When the medication is released from the inhaler, it enters the spacer, allowing the user to inhale it more slowly and deeply, improving delivery to the lungs and lowering the chance of side effects such as mouth thrush.

Furthermore, spacers are especially useful for people who struggle to coordinate when using inhalers, such as young children or those who have severe breathing problems. They can also ensure that more medication reaches the airways instead of being deposited in the mouth and throat.

Global Asthma Spacers Market Dynamics

The key market dynamics that are shaping the Asthma Spacers Market include:

Key Market Drivers

Increasing Prevalence of Asthma Globally: The increasing number of asthma sufferers globally is a major driver of the Asthma Spacers Market, as these devices improve the efficacy of inhaled treatments. According to the World Health Organization (WHO), asthma affected an estimated 262 million people in 2019 and claimed 461,000 lives. According to the Global Asthma Network's Global Asthma Report 2022, the prevalence of asthma has increased by 3.6% over the last decade. This expanding patient group demands more effective asthma control techniques, such as spacers.

Rising Air Pollution Levels and Environmental Triggers: Increasing air pollution and environmental variables exacerbate asthma symptoms, necessitating the use of effective medicine delivery methods such as spacers. According to the World Bank, 9 out of every 10 individuals breathe polluted air. According to a 2022 study published in The Lancet Planetary Health, air pollution causes an additional 1.8 million asthma cases in children each year. The link between air quality and asthma incidence highlights the growing necessity of asthma management devices, such as spacers.

Increasing Awareness and Education about Proper Inhaler Technique: The increased emphasis on patient education and good inhaler technique is driving the use of spacers to improve medicine delivery and prevent adverse effects. A systematic evaluation published in the Journal of Asthma in 2019 discovered that only 31% of patients used the correct inhaler technique. The use of spacers can greatly increase medicine distribution. The UK's National Institute for Health and Care Excellence (NICE) advises spacers for all children under the age of 12 who use pressurized metered-dose inhalers (pMDIs). According to Asthma UK, correct usage of spacers can boost drug delivery to the lungs by 10% to 50%.

Key Challenges:

High Costs: The high cost of asthma spacers is a key challenge for the market. Many asthma sufferers, particularly in low-income areas, struggle to buy spacers, limiting their accessibility and utilization. This cost barrier not only affects individual patients but also limits overall market growth because healthcare providers are hesitant to propose products that patients can't buy. As a result, effective asthma control techniques are often underutilized.

Competition from Alternative Devices: The Asthma Spacers Market faces additional competition from alternative devices such as nebulizers and dry powder inhalers (DPIs). Some consumers and healthcare providers prefer these options because they are thought to be easier to use or more effective. As a result, asthma spacer producers must work hard to differentiate their products by emphasizing their distinct benefits and ensuring they satisfy the changing needs of patients and healthcare systems. This competitive environment complicates market positioning and growth strategies for spacer makers.

Key Trends:

Growing Focus on Preventive Healthcare: Asthma spacers are becoming essential to comprehensive treatment regimens as healthcare systems place a greater emphasis on treating chronic disorders like asthma before they escalate. These devices improve medicine administration, lowering the number and severity of asthma episodes. This shift toward preventative interventions not only improves patient outcomes but also corresponds with larger healthcare cost-cutting goals, increasing demand for spacers.

Increased Adoption in Emerging Markets: With increased awareness of asthma care and the benefits of inhalation therapy, there is a growing demand for effective delivery devices in areas with high asthma prevalence. As healthcare infrastructures improve and access to asthma control products increases, manufacturers are working on these areas to broaden their reach. This development creates considerable growth opportunities for the Asthma Spacers Market as more patients seek better ways to manage their condition.

Global Asthma Spacers Market Regional Analysis

Here is a more detailed regional analysis of the Asthma Spacers Market:

North America:

According to Verified Market Research, North America is estimated to dominate the Asthma Spacers Market over the forecast period. North America, particularly the United States, has a high asthma burden, which drives demand for asthma control devices such as spacers. According to the Centers for Disease Control and Prevention (CDC), over 25 million Americans had asthma in 2019, accounting for roughly one in every thirteen persons. This includes 5.1 million children. The CDC also says that asthma causes 1.6 million emergency department visits in the United States each year. These high numbers highlight North America's sizable market for asthma control products, including spacers.

Furthermore, the well-developed healthcare system and large healthcare expenditures in North America contribute to the increased adoption of medical devices such as asthma spacers. According to the Organisation for Economic Cooperation and Development (OECD), the United States spent 17.8% of its GDP on healthcare in 2021, the most of any OECD country. Canada's healthcare spending was likewise high, accounting for 11.3% of GDP. This high level of healthcare spending makes medical equipment like asthma spacers more accessible and widely used.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth within the Asthma Spacers Market during the forecast period. The Asia Pacific region is rapidly urbanizing, resulting in increased air pollution, which is a major risk factor for asthma and promotes demand for asthma management devices such as spacers. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), Asia Pacific's urban population is expected to increase from 2.3 billion in 2019 to 3.5 billion in 2050. This urbanization is accompanied by deterioration in air quality. According to the World Health Organization (WHO), 98% of low- and middle-income cities in Asia Pacific with more than 100,000 people do not fulfill WHO air quality recommendations. The combination of urbanization and air pollution is anticipated to increase asthma prevalence, necessitating the use of appropriate management tools.

Furthermore, increased healthcare spending and improved healthcare infrastructure in the Asia Pacific are making medical equipment, such as asthma spacers, more accessible. According to the World Bank, health expenditure as a proportion of GDP in East Asia and the Pacific climbed from 6.4% in 2010 to 7.1% in 2019. In South Asia, it increased from 3.5% to 3.8% over the same period. This trend points to increased expenditure in healthcare, which is likely to improve access to asthma control devices such as spacers.

Global Asthma Spacers Market: Segmentation Analysis

The Asthma Spacers Market is segmented on the basis of Type and Distribution Channel.

Asthma Spacers Market, By Type

Volumatic
Aerochamber
Inspirease
Optichamber
Others

Based on Type, the market is segmented into Volumatic, Aerochamber, Inspirease, Optichamber, and Others. The Aerochamber segment is estimated to dominate the Asthma Spacers Market due to its ability to improve medicine delivery from metered-dose inhalers (MDIs) to the lungs, hence enhancing asthma treatment outcomes. Aerochambers are built with characteristics that assist inhalation and reduce medicine waste, making them a popular choice among both healthcare providers and consumers. Their widespread acceptance and demonstrated efficacy continue to fuel their market dominance.

Asthma Spacers Market, By Distribution Channel

Hospitals
Retail Pharmacy
Online Channel

Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacy, and Online Channel. The retail pharmacy segment is estimated to dominate the Asthma Spacers Market during the forecast period due to consumers' increased preference for easy access to pharmaceuticals and tailored guidance from pharmacy professionals. Retail pharmacies offer a diverse choice of asthma spacer options, allowing patients to select from a variety of brands and varieties. Furthermore, the expansion of retail pharmacies during the pandemic has made asthma control equipment more accessible, consolidating their dominant position in the distribution channel landscape.

Key Players

The "Asthma Spacers Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline Plc., Trudell Medical International, Conmed Corporation, Medical Development International, Royal Philips, Clement Clarke International Ltd., Lupin Limited, Vyaire Medical, Inc., Pari GmbH, AstraZeneca, Merck & Co.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Asthma Spacers Market Recent Developments
In November 2023, the faculty of medicine at the National University of Science and Technology (NUST) in Zimbabwe announced the invention of a cheap spacer specifically for children. These spacers are meant to be supplied widely throughout Africa at a low cost, perhaps saving thousands of lives.
In April 2021, Vyaire Medical Inc. (UK) announced the European launch of ArtiQ.PFT. ArtiQ.PFT is an artificial intelligence-powered automated tool for interpreting pulmonary function tests (PFTs). According to a multi-center study published in the European Respiratory Journal, the technology's algorithm identifies illness patterns in 82 percent of instances, but pulmonologists only identify 45 percent.

1 INTRODUCTION OF GLOBAL ASTHMA SPACERS MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL ASTHMA SPACERS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL ASTHMA SPACERS MARKET, BY TYPE

5.1 Overview
5.2 Volumatic
5.3 Aerochamber
5.4 Inspirease
5.5 Optichamber
5.6 Others

6 GLOBAL ASTHMA SPACERS MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
6.2 Hospitals
6.3 Retail Pharmacy
6.4 Online Channel

7 GLOBAL ASTHMA SPACERS MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East and Africa

8 GLOBAL ASTHMA SPACERS MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 GlaxoSmithKline Plc.
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Trudell Medical International
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Conmed Corporation
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Medical Development International
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Royal Philips
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Clement Clarke International Ltd.
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Lupin Limited
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Vyaire Medical Inc.
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Pari GmbH
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 AstraZeneca
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments